Detection methods predict differences in biology and survival in breast cancer patients

BMC Cancer

Volumn 12, Issue , 2012, Pages

  Redondo, Maximino ^a   Funez, Rafael ^b   Medina Cano, Francisco ^b   Rodrigo, Isabel ^b   Acebal, Mercedes ^c   Tellez, Teresa ^a   Roldan, M Jose ^a   Hortas, M Luisa ^a   Bellinvia, Ana ^b   Pereda, Teresa ^b   Domingo, Laia ^d   Morales Suarez Varela, María ^e   Sala, Maria ^d   Rueda, Antonio ^b  

^a UNIVERSITY OF MÁLAGA   (Spain)

^b HOSPITAL COSTA DEL SOL   (Spain)

^c HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^d UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^e UNIVERSITY OF VALENCIA   (Spain)

Author keywords

Apoptosis; Breast cancer; Detection methods; Proliferation; Survival

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; PROTEIN BCL 2;

ADULT; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER GROWTH; CANCER SCREENING; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; INCIDENTAL FINDING; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; PROTEIN EXPRESSION; SURVIVAL TIME; TUMOR VOLUME;

BREAST NEOPLASMS; CASE-CONTROL STUDIES; DISEASE PROGRESSION; EARLY DETECTION OF CANCER; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MAMMOGRAPHY; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS;

EID: 84870990870     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-12-604     Document Type: Article

References (29)

1. Vainio H. IARC Handbooks of cancer prevention: breast cancer screening 2002, IARC press, Lyon.
2. Moller H, Davies E. Over-diagnosis in breast cancer screening. BMJ 2006, 332:691-692.
3. Dillon MF, Hill AD, Quinn CM, O'Doherty A, Crown J, Fleming FJ, McDermott EW, O'Higgins N. Surgical intervention in screen-detected patients versus symptomatic patients with breast cancer. J Med Screen 2004, 11:130-134.
4. Welch HG, Black WC. Using autopsy series to estimate the disease "reservoir" for ductal carcinoma in situ of the breast: how much more breast cancer can we find?. Ann Intern Med 1997, 127:1023-1028.
5. Joensuu H, Lehtimäki T, Holli K, Elomaa L, Turpeenniemi-Hujanen T, Kataja V, Anttila A, Lundin M, Isola J, Lundin J. Risk for distant recurrence of breast cancer detected by mammography screening or other methods. JAMA 2004, 292:1064-1073.
6. Weaver DL, Rosenberg RD, Barlow WE, Ichikawa L, Carney PA, Kerlikowske K, Buist DS, Geller BM, Key CR, Maygarden SJ, Ballard-Barbash R. Pathologic findings from the breast cancer surveillance consortium: population-based outcomes in women undergoing biopsy after screening mammography. Cancer 2006, 106:732-42.
7. Shen Y, Yang Y, Inoue LY, Munsell MF, Miller AB, Berry DA. Role of detection method in predicting breast cancer survival: analysis of randomized screening trials. J Natl Cancer Inst 2005, 97:1195-1203.
8. Wishart GC, Greenberg DC, Britton PD, Chou P, Brown CH, Purushotham AD, Duffy SW. Screen-detected vs symptomatic breast cancer: is improved survival due to stage migration alone?. Br J Cancer 2008, 98:1741-1744.
9. Dawson SJ, Duffy SW, Blows FM, Driver KE, Provenzano E, LeQuesne J, Greenberg DC, Pharoah P, Caldas C, Wishart GC. Molecular characteristics of screen-detected vs symptomatic breast cancers and their impact on survival. Br J Cancer 2009, 101:1338-1344.
10. Burrell HC, Sibbering DM, Wilson AR, Pinder SE, Evans AJ, Yeoman LJ, Elston CW, Ellis IO, Blamey RW, Robertson JF. Screening interval breast cancers: mammographic features and prognosis factors. Radiology 1996, 199:811-817.
11. Brekelmans CT, Peeters PH, Deurenberg JJ, Collette HJ. Survival in interval breast cancer in the DOM screening programme. Eur J Cancer 1995, 31A:1830-1835.
12. Redondo M, García J, Villar E, Rodrigo I, Perea-Milla E, Serrano A, Morell M. Major histocompatibility complex status in breast carcinogenesis and relationship to apoptosis. Hum Pathol 2003, 34:1283-9.
13. Lacroix M, Toillon RA, Leclercq G. Stable portrait of breast tumours during progression: data from biology, pathology and genetics. Endocr Relat Cancer 2004, 11:497-522.
14. Bernards R, Weinberg RA. A progression puzzle. Nature 2002, 418:823.
15. McGuire WL. Prognostic factors for recurrence and survival in human breast cancer. Breast Cancer Res Treat 1987, 10:5-9.
16. American Society of Clinical Oncology Clinical practice guidelines for the use of tumour markers in breast and colorectal cancers. J Clin Oncol 1996, 14:2843-2877. American Society of Clinical Oncology.
17. Lipponen P, Aaltomaa S, Kosma VM, Syrjänen K. Apoptosis in breast cancer as related to histopathological characteristics and prognosis. Eur J Cancer 1994, 30A:2068-2073.
18. Villar E, Redondo M, Rodrigo I, García J, Avila E, Matilla A. bcl-2 expression and apoptosis in primary and metastatic breast carcinomas. Tumour Biol 2001, 22:137-145.
19. Bhargava V, Kell DL, van de Rijn M, Warnke RA. Bcl2 immunoreactivity in breast carcinoma correlates with hormone receptor positivity. Am J Pathol 1994, 145:535-540.
20. Callagy GM, Pharoah PD, Pinder SE, Hsu FD, Nielsen TO, Ragaz J, Ellis IO, Huntsman D, Caldas C. Bcl-2 is a prognostic marker in breast cancer independently of the Nottingham Prognostic Index. Clin Cancer Res 2006, 12:2468-2475.
21. Callagy GM, Webber MJ, Pharoah PD, Caldas C. Meta-analysis confirms BCL2 is an independent prognostic marker in breast cancer. BMC Cancer 2008, 8:153.
22. Kallioniemi OP, Kärkkäinen A, Auvinen O, Mattila J, Koivula T, Hakama M. DNA flow cytometric analysis indicates that many breast cancers detected in the first round of mammographic screening have a low malignant potential. Int J Cancer 1988, 42:697-702.
23. Uyterlinde AM, Baak JP, Schipper NW, Peterse HJ, Meijer JW, Vooys PG, Matze E. Prognostic value of morphometry and DNA flow-cytometry features of invasive breast cancers detected by population screening: comparison with control group of hospital patients. Int J Cancer 1991, 48:173-181.
24. Crosier M, Scott D, Wilson RG, Griffiths CD, May FE, Westley BR. Differences in Ki67 and c-erbB2 expression between screen-detected and true interval breast cancers. Clin Cancer Res 1999, 5:2682-2688.
25. Olivotto IA, Mates D, Kan L, Fung J, Samant R, Burhenne LJ. Prognosis, treatment, and recurrence of breast cancer for women attending or not attending the Screening Mammography Program of British Columbia. Breast Cancer Res Treat 1999, 54:73-81.
26. Magee B, Stewart AL, Swindell R. Outcome of radiotherapy after breast conserving surgery in screen detected breast cancers. Clin Oncol 1999, 11:40-45.
27. Wintzer HO, Zipfel I, Schulte-Mönting J, Hellerich U, von Kleist S. Ki-67 immunostaining in human breast tumours and its relationship to prognosis. Cancer 1991, 67:421-428.
28. Merkel DE, McGuire WL. Ploidy, proliferative activity and prognosis. DNA flow cytometry of solid tumours. Cancer 1990, 65:1194-1205.
29. Redondo M, Rodrigo I, Pereda T, Funez R, Acebal M, Perea-Milla E, Jimenez E. Effects of emergency admission and delays on prognosis in patients with breast carcinoma. Supp Care Cancer 2009, 17:595-599.